Novacyt S.A (NVYTF)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Novacyt S.A, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Novacyt S.A (NVYTF) has returned -5.90% so far this year and -25.12% over the past 12 months.

Based on dividend-adjusted daily data since Feb 3, 2020, NVYTF's average daily return is +0.21%, while the average monthly return is +4.19%. At this rate, your investment would double in approximately 1.4 years.

Historically, 34% of months were positive and 66% were negative. The best month was Feb 2020 with a return of +194.2%, while the worst month was Jan 2022 at -50.8%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 6 months.

On a daily basis, NVYTF closed higher 8% of trading days. The best single day was Feb 18, 2020 with a return of +144.8%, while the worst single day was Apr 9, 2021 at -38.3%.

Novacyt S.A has an annualized alpha of 73.96%, beta of -0.15, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since February 11, 2020.

• This stock tended to rise when S&P 500 Index fell (downside capture of -149.54%), but participation in market rallies was also limited (-47.98%) — a profile typical of counter-cyclical assets.
• Beta of -0.15 may look defensive, but with R² of 0.00 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

NVYTF ranks 5 for risk / return — in the bottom 5% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for Novacyt S.A (NVYTF) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Novacyt S.A. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Novacyt S.A was 97.00%, occurring on Jan 2, 2026. The portfolio has not yet recovered.

The current Novacyt S.A drawdown is 97.00%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Novacyt S.A over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Novacyt S.A is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.